Suspended

COVID AMBU 60Epidemiological Observation of Ambulatory COVID-19 Patients in Oise Region

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

COVID-19+9

+ Coronaviridae Infections

+ Infections

Until 99 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: March 2020
See protocol details

Summary

Principal SponsorMaison de Sante Pluridisciplinaire de Creil
Study ContactSvetlane DIMI, M.D
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2020

Actual date on which the first participant was enrolled.

COVID-19, a respiratory disease caused by the coronavirus SARS-Cov-2, has spread globally since December 2019. In France, the Oise region was one of the first to experience a significant outbreak, with over 4,000 confirmed cases. Most COVID-19 patients (around 80%) do not require hospitalization, but there is limited information about this specific group in France. This study aims to fill this gap, providing valuable insights that could lead to improved care and guidance for ambulatory COVID-19 patients. The study focuses on the Oise region, where the virus has significantly impacted the community. The study is observational, meaning participants will continue with their usual care routines. Researchers will collect data on the patients' health and the initial management of their condition. The primary goal is to create a detailed clinical description of COVID-19 cases in ambulatory patients. This includes understanding the epidemiological characteristics and identifying early signs of severity. The findings could help in developing clearer recommendations for the management of COVID-19 in outpatients.

Official TitleMulticentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.
NCT04363099
Principal SponsorMaison de Sante Pluridisciplinaire de Creil
Study ContactSvetlane DIMI, M.D
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Until 99 Years

Range of ages for which participants are eligible to join.

Conditions

Pathology

COVID-19Coronaviridae InfectionsInfectionsLung DiseasesPneumoniaPneumonia, ViralRespiratory Tract DiseasesRespiratory Tract InfectionsRNA Virus InfectionsVirus DiseasesCoronavirus InfectionsNidovirales Infections

Criteria

2 inclusion criteria required to participate
patients with covid 19 symptoms
patients who had a contact with a person PCR Covid 19+
1 exclusion criteria prevent from participating
none

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Msp de Creil

Creil, FranceOpen Msp de Creil in Google Maps
SuspendedOne Study Center